Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company that went public in 2023 through a SPAC combination, operating in the life sciences and biotechnology sector. The company filed a Form 10-Q with the Securities and Exchange Commission on December 15, 2023, reflecting its active reporting status as a post-combination public issuer. Abpro is engaged in the development of bispecific antibody therapeutics with applications in oncology and other serious disease areas. Analysts and investors seeking comprehensive filing histories, deal timelines, and post-merger performance metrics for ABP and the broader SPAC universe can sign up for full data access on SpacDesk.